Payment overview · 2025
General Payments
$4,859.98
219 reported records · 34 companies
Healthcare provider profile · identity verified
Marcus Mayus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENWICH, CT · NPI 1073734935
Verified facts
What the public records show
CMS Open Payments records show Marcus Mayus, M.D. received $4,859.98 in general payments during 2025 across 219 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Qulipta, Synthroid, Vraylar, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyosted by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $989.20 | 20.4% | 54 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $454.93 | 9.4% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $450.60 | 9.3% | 27 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $344.95 | 7.1% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $329.19 | 6.8% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $233.23 | 4.8% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $200.31 | 4.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $175.15 | 3.6% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $168.68 | 3.5% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $165.85 | 3.4% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $154.74 | 3.2% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $137.72 | 2.8% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $115.89 | 2.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $106.89 | 2.2% | 5 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $106.24 | 2.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.07 | 2.0% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.35 | 1.9% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $85.25 | 1.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $78.99 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.04 | 1.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.47 | 0.7% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $34.55 | 0.7% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $29.89 | 0.6% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.02 | 0.5% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.41 | 0.5% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $24.03 | 0.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.02 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.16 | 0.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.08 | 0.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $19.00 | 0.4% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $18.78 | 0.4% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.76 | 0.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.43 | 0.4% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.11 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,780.99 | 218 |
| Education | $78.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $611.90 | 22 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $423.83 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $344.95 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $321.84 | 19 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $319.87 | 29 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $235.74 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $219.88 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $187.55 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $175.90 | 8 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $175.15 | 7 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $175.15 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $168.68 | 10 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $165.85 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $154.74 | 9 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $154.22 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $137.72 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $131.95 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $115.89 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $106.89 | 5 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $106.24 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $96.07 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $96.07 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $85.25 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $78.92 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.55 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.55 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $70.63 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.61 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $55.78 | 3 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $48.48 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $47.04 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $46.09 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $29.89 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29.74 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 177 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 117 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 50 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 155 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
155 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
117 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
50 | 48 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 927 | 249 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 837 | 266 |
| Atorvastatin Calcium | Atorvastatin Calcium | 836 | 240 |
| Losartan Potassium | Losartan Potassium | 543 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 167 |
| Pantoprazole Sodium | Pantoprazole Sodium | 476 | 162 |
| Metformin Hcl | Metformin Hcl | 382 | 118 |
| Escitalopram Oxalate | Escitalopram Oxalate | 353 | 112 |
| Azithromycin | Azithromycin | 314 | 191 |
| Furosemide | Furosemide | 255 | 81 |
| Lisinopril | Lisinopril | 249 | 70 |
| Gabapentin | Gabapentin | 247 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 75 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 226 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 79 |
| Montelukast Sodium | Montelukast Sodium | 220 | 63 |
| Meloxicam | Meloxicam | 213 | 83 |
| Alprazolam | Alprazolam | 210 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 70 |
| Allopurinol | Allopurinol | 205 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 59 |
| Methylprednisolone | Methylprednisolone | 199 | 143 |
| Simvastatin | Simvastatin | 194 | 57 |
| Atenolol | Atenolol | 187 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 65 |
| Prednisone | Prednisone | 186 | 100 |
| Carvedilol | Carvedilol | 179 | 49 |
| Eliquis | Apixaban | 177 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 174 | 54 |
| Cefuroxime | Cefuroxime Axetil | 171 | 128 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 52 |
| Synthroid | Levothyroxine Sodium | 155 | 46 |
| Ezetimibe | Ezetimibe | 153 | 51 |
| Omeprazole | Omeprazole | 130 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 34 |
| Mounjaro | Tirzepatide | 117 | 27 |
| Donepezil Hcl | Donepezil Hcl | 109 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 46 |
| Sertraline Hcl | Sertraline Hcl | 103 | 38 |
| Bupropion Xl | Bupropion Hcl | 101 | 34 |
| Finasteride | Finasteride | 96 | 29 |
| Xarelto | Rivaroxaban | 92 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 79 |
| Lorazepam | Lorazepam | 89 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 30 |
| Trazodone Hcl | Trazodone Hcl | 88 | 25 |
| Spironolactone | Spironolactone | 84 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 81 | 23 |
| Ozempic | Semaglutide | 79 | 21 |
| Clonazepam | Clonazepam | 78 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 23 |
| Potassium Chloride | Potassium Chloride | 78 | 21 |
| Tramadol Hcl | Tramadol Hcl | 78 | 33 |
| Mirtazapine | Mirtazapine | 77 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 20 |
| Januvia | Sitagliptin Phosphate | 73 | 20 |
| Linzess | Linaclotide | 71 | 18 |
| Jardiance | Empagliflozin | 69 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 19 |
| Diazepam | Diazepam | 64 | 26 |
| Valsartan | Valsartan | 64 | 20 |
| Celecoxib | Celecoxib | 62 | 21 |
| Nystatin | Nystatin | 62 | 28 |
| Metformin Hcl Er | Metformin Hcl | 61 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 48 |
| Eszopiclone | Eszopiclone | 60 | 24 |
| Colchicine | Colchicine | 59 | 27 |
| Mupirocin | Mupirocin | 59 | 41 |
| Liothyronine Sodium | Liothyronine Sodium | 58 | 21 |
| Valacyclovir | Valacyclovir Hcl | 58 | 34 |
| Lansoprazole | Lansoprazole | 54 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 37 |
| Famotidine | Famotidine | 52 | 16 |
| Ondansetron Odt | Ondansetron | 50 | 25 |
| Paxlovid | Nirmatrelvir/Ritonavir | 50 | 48 |
| Fluconazole | Fluconazole | 49 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 17 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 11 |
| Hydrocortisone | Hydrocortisone | 48 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 21 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 43 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | 17 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Digoxin | Digoxin | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 20 |
| Ramipril | Ramipril | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 13 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Clotrimazole | Clotrimazole | 32 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 21 |
| Levofloxacin | Levofloxacin | 32 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 11 |
| Minoxidil | Minoxidil | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 24 |
| Metronidazole | Metronidazole | 29 | 25 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 12 |
| Azelastine Hcl | Azelastine Hcl | 27 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 14 |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 19 |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Eplerenone | Eplerenone | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 19 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Clarithromycin | Clarithromycin | 17 | 13 |
| Glipizide | Glipizide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Qulipta | Atogepant | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Xyosted | Testosterone Enanthate | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,859.98 · 219 records | ABBVIE INC. | ABRYSVO, AMVUTTRA, AREXVY, AZMIRO, Auvelity, Azstarys, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FARXIGA, GARDASIL 9, GEMTESA, Hillrom - Carnation Ambulatory Monitor, IBSRELA, ImmunoCAP, JARDIANCE, KRYSTEXXA, Kerendia, LAGEVRIO, LEQVIO, LOREEV XR, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, RHYTHM EXPRESS, Rybelsus, SHINGRIX, SYNTHROID, Symbravo, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, WELLBUTRIN, Wegovy, XIFAXAN, XYOSTED, Xhance, ZAVZPRET, ZEPBOUND, ZURZUVAE | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error